Bayer’s recent announcement regarding its intention to seek regulatory approval ...
AstraZeneca has made a strategic move into the realm of rare endocrinology with ...
AstraZeneca’s decision to integrate Fusion Pharmaceuticals into its cancer divis...
A comprehensive series of sophisticated examinations conducted by researchers re...
Ever since facing its initial setback with the FDA half a decade ago, Lexicon Ph...
For patients with recurrent glioblastoma, the chimeric antigen receptor T-cell (...
Since its initial rejection by the FDA approximately five years ago, Lexicon Pha...
The pharmaceutical giant Pfizer revealed positive results from a late-stage stud...
HiLabs, a health technology enterprise powered by artificial intelligence, is de...
Eli Lilly’s recent breakthrough in eczema treatment represents a stride in addre...
In its pursuit of Regeneron and Sanofi’s Dupixent in the treatment of prurigo no...
Iovance Biotherapeutics has had a partial clinical hold imposed by the FDA. This...
Merck KGaA has been brought on board by the Massachusetts biotechnology company ...
In a recent unveiling at the 2024 Conference on Retroviruses and Opportunistic I...
NovAliX, a specialized contract research company that is committed to facilitati...
Bispecific T-cell engagers are gaining prominence in oncology, yet this hasn’t d...
